Trials / Completed
CompletedNCT04924101
Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants With Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the use of investigational agents (MK-4830, boserolimab (MK-5890) and lenvatinib (MK-7902)) in combination with pembrolizumab (MK-3475) and etoposide/platinum chemotherapy for the first-line treatment of participants with extensive-stage small cell Lung Cancer (ES-SCLC). No formal hypothesis testing will be performed for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Pembrolizumab | IV infusion |
| BIOLOGICAL | MK-4830 | IV infusion |
| BIOLOGICAL | Boserolimab | IV infusion |
| DRUG | Lenvatinib | Oral capsule |
| DRUG | Etoposide | IV infusion |
| DRUG | Cisplatin | IV infusion |
| DRUG | Carboplatin | IV infusion |
Timeline
- Start date
- 2021-07-15
- Primary completion
- 2025-06-23
- Completion
- 2025-06-23
- First posted
- 2021-06-11
- Last updated
- 2025-07-23
Locations
49 sites across 11 countries: United States, Austria, Canada, Hungary, Israel, Italy, Poland, Russia, South Korea, Spain, Switzerland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04924101. Inclusion in this directory is not an endorsement.